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Abstract
Regulated transcription controls the diversity, developmental pathways and spatial organization of 
the hundreds of cell types that make up a mammal. Using single-molecule cDNA sequencing, we 
mapped transcription start sites (TSSs) and their usage in human and mouse primary cells, cell 
lines and tissues to produce a comprehensive overview of mammalian gene expression across the 
human body. We find that few genes are truly ‘housekeeping’, whereas many mammalian 
promoters are composite entities composed of several closely separated TSSs, with independent 
cell-type-specific expression profiles. TSSs specific to different cell types evolve at different rates, 
whereas promoters of broadly expressed genes are the most conserved. Promoter-based expression 
analysis reveals key transcription factors defining cell states and links them to binding-site motifs. 
The functions of identified novel transcripts can be predicted by coexpression and sample 
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ontology enrichment analyses. The functional annotation of the mammalian genome 5 
(FANTOM5) project provides comprehensive expression profiles and functional annotation of 
mammalian cell-type-specific transcriptomes with wide applications in biomedical research.
The mammalian genome encodes the instructions to specify development from the zygote 
through gastrulation, implantation and generation of the full set of organs necessary to 
become an adult, to respond to environmental influences, and eventually to reproduce. 
Although the genome information is the same in almost all cells of an individual, at least 
400 distinct cell types1 have their own regulatory repertoire of active and inactive genes. 
Each cell type responds acutely to alterations in its environment with changes in gene 
expression, and interacts with other cells to generate complex activities such as movement, 
vision, memory and immune response.
Identities of cell types are determined by transcriptional cascades that start initially in the 
fertilised egg. In each cell lineage, specific sets of transcription factors are induced or 
repressed. These factors together provide proximal and distal regulatory inputs that are 
integrated at transcription start sites (TSSs) to control the transcription of target genes. Most 
genes have more than one TSS, and the regulatory inputs that determine TSS choice and 
activity are diverse and complex (reviewed in ref. 2).
Unbiased annotation of the regulation, expression and function of mammalian genes 
requires systematic sampling of the distinct mammalian cell types and methods that can 
identify the set of TSSs and transcription factors that regulate their utilization. To this end, 
the FANTOM5 project has performed cap analysis of gene expression (CAGE)3 across 975 
human and 399 mouse samples, including primary cells, tissues and cancer cell lines, using 
single-molecule sequencing3 (Fig. 1; see the full sample list in Supplementary Table 1).
CAGE libraries were sequenced to a median depth of 4 million mapped tags per sample 
(Supplementary Methods) to produce a unique gene expression profile, focused specifically 
on promoter utilization. CAGE has advantages over RNA-seq or microarrays for this 
purpose, because it permits separate analysis of multiple promoters linked to the same 
gene13. Moreover, we show in an accompanying manuscript4 that the data can be used to 
locate active enhancers, and to provide numerous insights into cell-type-specific 
transcriptional regulatory networks (see the FANTOM5 website http://
fantom.gsc.riken.jp/5). The data extend and complement the recently published ENCODE5 
data, and microarray-based gene expression atlases6 to provide a major resource for 
functional genome annotation and for understanding the transcriptional networks 
underpinning mammalian cellular differentiation.
The FANTOM5 promoter atlas
Single molecule CAGE profiles were generated across a collection of 573 human primary 
cell samples (~ 3 donors for most cell types) and 128 mouse primary cell samples, covering 
most mammalian cell steady states. This data set is complemented with profiles of 250 
different cancer cell lines (all available through public repositories and representing 154 
distinct cancer subtypes), 152 human post-mortem tissues and 271 mouse developmental 
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tissue samples (Fig. 1a; see the full sample list in Supplementary Table 1). To facilitate data 
mining all samples were annotated using structured ontologies (Cell Ontology7, Uberon8, 
Disease Ontology9). The results of all analyses are summarized in the FANTOM5 online 
resource (http://fantom.gsc.riken.jp/5). We also developed two specialized tools for 
exploration of the data. ZENBU, based on the genome browser concept, allows users to 
interactively explore the relationship between genomic distribution of CAGE tags and 
expression profiles10. SSTAR, an interconnected semantic tool, allows users to explore the 
relationships between genes, promoters, samples, transcription factors, transcription factor 
binding sites and coexpressed sets of promoters. These and other ways to access the data are 
described in more detail in Supplementary Note 1.
CAGE peak identification and thresholding
To identify CAGE peaks across the genome we developed decomposition-based peak 
identification (DPI; described in Supplementary Methods; Extended Data Fig. 1). This 
method first clusters CAGE tags based on proximity. For clusters wider than 49 base pairs 
(bp) it attempts to decompose the signal into non-overlapping sub-regions with different 
expression profiles using independent component analysis11. Sample-and genome-wide, DPI 
identified 3,492,729 peaks in human and 2,088,255 peaks in mouse. To minimize the 
fraction of peaks3 that map to internal exons (which could exist due to post-transcriptional 
cleavage and recapping of RNAs12), and enrich for TSSs, we applied tag evidence 
thresholds to define robust and permissive subsets (described in more detail in 
Supplementary Methods and summarized in Table 1). Specifically the robust threshold, 
which is used for most of the analyses presented here, enriched for peaks at known 5′ ends 
compared to known internal exons by twofold (that is, two-thirds of the peaks hitting known 
full-length transcript models hit the 5′ end). A flow diagram showing the relationship 
between samples, peaks, thresholding and subsets used in each analysis is provided in the 
Supplementary Figure 1. Supporting evidence that the peaks are genuine TSSs, based upon 
support from expressed sequence tags (ESTs), histone H3 lysine 4 trimethylation 
(H3K4Me3) marks and DNase hypersensitive sites is provided in Supplementary Note 2.
Figure 1b illustrates the 266 bp spanning transcription initiation region of B4GALT1, where 
6 independent robust peaks were identified by DPI, each with a unique regulatory pattern 
(Fig. 1c). A total of 58% of human and 56% of mouse robust peaks occur in such composite 
transcription initiation regions, defined as clusters of robust peaks within 100 bases of each 
other. More than half of these contain peaks with statistically significant differences in 
expression profiles (63% of human and 54% of mouse composite transcription initiation 
regions; likelihood ratio test, false discovery rate (FDR) < 1%, Extended Data Fig. 1d). 
Supplementary Tables 2 and 3 summarize public domain EST evidence that these 
independent peaks contained within composite transcription initiation regions give rise to 
long RNAs.
Known gene coverage in FANTOM5
To provide annotation of the CAGE peaks, the distance between individual peaks and the 5′ 
ends of known full-length transcripts was determined and then peaks within 500 bases of the 
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5′ end of known transcript models were assigned to that gene (see Supplementary Methods, 
Table 1). To provide names for each TSS region, peaks identified at the permissive 
threshold were ranked by the total number of tags supporting each and then sequentially 
numbered (for example, p1@GFAP corresponds to the promoter of GFAP which has the 
highest tag support). From these annotations, TSS for 91% of human protein coding genes 
(as defined by the HUGO Gene Nomenclature Committee) were supported by robust CAGE 
peaks, and 94% at the permissive threshold (Supplementary Note 3). The atlas also detected 
signals from the promoters of short RNA primary transcripts, and long non-coding RNAs. In 
comparison to the previous FANTOM3 and 4 projects, FANTOM5 measured expression at 
an additional 4,721 human and 5,127 mouse RefSeq genes. The inclusion of primary cells, 
cell lines and tissues in the atlas provided greater coverage than any of the sample types 
alone (Fig. 1d) and the primary cell samples in particular were a rich source of unannotated 
peaks (Fig. 1e).
Mammalian promoter architectures
Mammalian promoters can be classified as broad or sharp types, based upon local spread of 
TSSs along the genome13. The FANTOM5 data confirmed this general observation 
(Extended Data Fig. 2), however, for the first time the greater depth of sequencing enabled 
identification of the preferred TSS within broad promoters. Taking each library in turn, 
using the location of the dominant TSS (that is, the TSS with the highest number of tags), 
we searched for phased WW dinucleotides (AA/AT/TA/TT) associated with nucleosome 
location14 (Extended Data Fig. 2). Remarkably, on a genome-wide scale, there was a 
periodic spacing of WW motifs with a 10.5 bp repeat downstream of the dominant TSS, 
exactly as shown previously for well-phased H2A.Z nucleosomes14 (Extended Data Fig. 
2d). The precise phasing was supported further by the pattern of H2A.Z and H3K4me3 
chromatin immunoprecipitation sequencing (ChIP-seq) signal seen around TSS in CD14+ 
monocytes and frontal lobe respectively (Extended Data Fig. 2e, f). This observation 
indicates that the positioned nucleosome is a key indicator of start site preference in broad 
promoters.
Expression levels and tissue specificity
The raw tag counts under the DPI peak coordinates were used to generate an expression 
table across the entire collection. Normalized tags per million (TPM) were then calculated 
using the relative log expression (RLE) method in edgeR15. Almost all peaks (96%) were 
reproducibly detected above 1 TPM in at least two samples, but most were detected in less 
than half the samples. Examining the distribution of expression level and breadth across the 
collection, we classified the 185K robust human peak expression profiles as non-ubiquitous 
(cell-type-restricted, 80%), ubiquitous-uniform (‘housekeeping’, 6%) or ubiquitous-non-
uniform (14%) (Fig. 2a, b). We define ubiquitous as detected in more than 50% of samples 
(median >0.2 TPM) and uniform as a less than tenfold difference between maximum and 
median expression. Estimation using the smaller mouse expression data set or human 
primary cell, cell line or tissue data subsets resulted in different fractions, yet in all cases 
ubiquitous-uniform expression profiles were in the minority (Extended Data Fig. 3a–e). 
Alternative measures such as richness index and Shannon entropy confirm that only a minor 
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fraction of transcripts can be considered as genuine housekeeping genes with broad and 
uniform expression (Supplementary Note 4 and Supplementary Table 4 for a list of 
housekeeping genes). In addition many of the 1,225 known genes that were missed in the 
collection are known to be specifically expressed in cell types that are not easily procured; 
indicating that even more of the mammalian transcriptome has a cell-type-restricted 
expression pattern (Supplementary Note 3). In overview, the data confirm the argument that 
most genes are regulated in a tissue-dependent manner16. According to Gene Ontology 
enrichment analysis17 of genes within each of the three classes (Supplementary Table 5), the 
non-ubiquitous genes were enriched for proteins involved in cell–cell signalling, plasma 
membrane receptors, cell adhesion molecules and signal transduction, whereas genes in the 
housekeeping set were enriched for components of the ribonucleoprotein complex and RNA 
processing. The ubiquitous-non-uniform set was enriched for cell cycle genes, with 204 of 
the 268 human genes annotated with the ‘mitotic cell cycle’ term, a reflection of the fact that 
the fraction of actively proliferating cells inevitably varies greatly across the collection.
Finally, of the 104, 859 peaks expressed at 10 TPM (~ 3 copies per cell18) or greater, an 
average primary cell sample expressed a median of 8, 757 including peaks for 430 
transcription factor mRNAs (Extended Data Fig. 3f, g).
Promoter conservation between human and mouse
Regulatory regions such as transcription factor binding sites are often, but not always, 
located in conserved and orthologous regions19. Overall human TSSs were significantly 
enriched in evolutionarily conserved regions compared to the genome-wide null expectation, 
with 38% overlapping previously defined mammalian constrained elements (Fisher’s exact 
test, odds ratio 10.2, P value < 2.2 × 10−16; see Supplementary Methods). Despite this 
general level of conservation, there is evidence of extensive evolutionary remodelling of 
transcription initiation. For example, 43% (79,670 out of 184,476) of human TSSs could not 
be aligned to the mouse genome, and 39% (45,926 out of 116,277) of mouse TSSs could not 
be aligned to the human genome (Supplementary Methods). Alignment between species 
decayed as a function of neutral sequence divergence (Fig. 3). Housekeeping TSSs showed 
highest TSS conservation, whereas the TSSs of non-coding RNAs were less conserved than 
those of protein-coding TSSs. Indeed, the alignment of promoters of broadly expressed non-
coding transcripts was not greatly different from randomly selected genomic sites (Fig. 3a). 
However, it is important to note that the random permutations inevitably overlap constrained 
elements, so cannot be considered representative of neutral evolution.
TSSs that were highly-restricted or biased in their expression to a single cell type or tissue 
were more likely to be gained or lost through evolution (Fig. 3a). TSSs preferentially 
expressed in fibroblasts, chondrocytes and pre-adipocytes were among the most conserved, 
whereas those enriched in T-cells, macrophages, dendritic cells, whole blood and endothelial 
cells were the most likely to be gained or lost (Fig. 3b). This suggests a more rapidly 
evolving immune system. It also suggests contributions of relaxed constraint and positive 
selection to the remodelling of transcription initiation through the insertion and deletion of 
promoter sequences.
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To enable comparative analysis, we projected the expression patterns from one species to 
the other (Extended Data Fig. 4) and provide the peak position and orthologous expression 
profile through a cross-species track in ZENBU10. Only 54% and 61% of human and mouse 
conserved TSSs (of protein coding genes) had an orthologous peak in the other species. This 
increased to 61% and 63% respectively for TSSs from well matched samples (for example, 
human and mouse hepatocytes), however, surprisingly, almost 40% of conserved TSS do not 
appear to be used even in the matched cells (Supplementary Table 6).
Features of cell-type-specific promoters
Carrying out a systematic de novo motif discovery analysis in cell-type-specific promoters, 
recovered motifs similar to the binding motifs of transcription factors known to be relevant 
to the corresponding cellular states (Extended Data Fig. 5a–c and described in 
Supplementary Note 5). Examining general promoter features many CpG island (CGI) based 
promoters (54%) and most non-CGI-non-TATA promoters (92%) had non-ubiquitous 
expression profiles (Extended Data Fig. 3k–n). Although CGI promoters are generally 
associated with housekeeping genes, we observed a subset with highly cell-type-restricted 
expression profiles (right tail of Extended Data Fig. 6a). Examining CGI and non-CGI 
promoters separately we find that cell-type-specific promoters of both classes were enriched 
for binding of cell-type-specific transcription factors (evidenced by over-representation of 
motifs and bound sites in public ChIP-seq data sets). For the human hepatocellular 
carcinoma cell line HepG2 we observed enrichment of liver-specific transcription factors 
(HNF4, FOXA2, and TCF7L2) at both CGI and non-CGI HepG2 specific promoters 
(Extended Data Fig. 6b, c; similar examples are shown in Extended Data Figs 5d and 7). As 
noted in the accompanying analysis4, both cell-type-specific CGI and non-CGI promoters 
tend to have proximal high-specificity enhancers (Extended Data Fig. 6d). This indicates 
that specific expression at CGI promoters uses the same type of signals as non-CGI 
promoters: proximal transcription factor motifs and high-specificity enhancers.
Of note, a small number of highly abundant RNAs account for 20% or more of the reads in 
some libraries: HBB, SMR3B, STATH, PRB4, CLPS, HTN3, SERPINA1, CTRB2, CPB1, 
CPA1 and MALAT1. Although the abundance of these transcripts is a function of their 
relatively stability as well as rate of initiation, a modest but significant over representation of 
ETS and YY1 sites was found in highly expressed promoters compared to weakly expressed 
ones (Extended Data Fig. 5g). Although the different motif composition may contribute to 
expression levels, the accompanying manuscript4 shows that arrays of enhancers with 
similar usage20 probably contribute to the higher maximal expression rate.
Key cell-type-specific transcription factors
Among 1,762 human and 1,516 mouse transcription factors compiled from the 
literature21–23, promoter level expression profiles for 1,665 human transcription factors 
(94%) and 1,382 mouse transcription factors (91%) were obtained (Supplementary Tables 7, 
8 and 9 and Supplementary Note 6). The distribution of expression levels and cell-type or 
tissue-specificity of transcription factors (Extended Data Fig. 3f–j) and the number of robust 
promoter peaks per transcription factor gene was similar to coding genes in general (4.8 
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compared to 4.6). In any given primary cell type, a median of 430 (306 to 722) transcription 
factors were expressed at 10 TPM or above (~ 3 copies per cell based on 300,000 mRNAs 
per cell18) (Extended Data Fig. 3g).
Clustering transcription factors by expression profile revealed sets of transcription factors 
specifically enriched in each cell type (Extended Data Fig. 8). For each primary cell sample 
we have made available ranked lists of transcription factors based on their promoter 
expression in the sample relative to the median across the collection (http://
fantom.gsc.riken.jp/5/sstar/Browse_samples). For most cell types we found one transcription 
factor that was very highly enriched (≥100-fold), 23 highly enriched transcription factors (≥ 
tenfold) and 82 moderately enriched transcription factors (≥ fivefold) (numbers of 
transcription factors are based on median number of transcription factors observed at each 
enrichment threshold across the primary cell samples). To demonstrate their likely relevance 
we systematically reviewed phenotypes of transcription factor knockout mice at the MGI 
(see Supplementary Note 7). The clear connection between tissue-specific expression 
profiles and relevant knockout phenotypes is summarized in Supplementary Table 10. For 
example, in mouse inner ear hair cells, knockout of six of the top 20 most enriched 
transcription factor genes in mouse (Pou3f4 (ref. 24), Sox2 (ref. 25), Egr2, Six1 (ref. 26), 
Fos27, Tbx18 (ref. 28)) as well as patient mutations in a further four top transcription factor 
genes (POU4F3 (ref. 29), ZIC2 (ref. 30), SOX10 (ref. 31), FOXF2 (ref. 32)) resulted in 
hearing-related defects. Similarly, mouse knockouts or patients with mutations in the 
transcription factors enriched in osteoblasts (CREB3L1 (ref. 33), DLX5 (ref. 34), EBF2 (ref. 
35), HAND2 (ref. 36), HOXC5 (ref. 37), NFIX38, PRRX1 (ref. 39), PRRX2 (ref. 40), SIX1 
(ref. 41), TWIST1 (ref. 42), SHOX43, Six2 (ref. 44)) had bone and osteoblast phenotypes. A 
substantial fraction of top transcription factors (61% of mouse and 40% of human 
transcription factors) have relevant phenotypes recorded in knockout mice (Supplementary 
Table 10).
Inferring function from expression profiles
Taking a pair-wise Pearson correlation matrix of the promoter expression profiles we carried 
out MCL clustering45 (Supplementary Methods) to group promoters that share similar 
expression profiles across the atlas. Figure 4 shows a graphical overview of the structure of 
the data (and the mouse counterpart is shown in Extended Data Fig. 9). We find 6,030 cases 
of named genes with alternative promoters participating in two or more coexpression 
clusters (Extended Data Fig. 10). To evaluate and annotate these coexpressed groups, we 
tested for enrichment in specific Gene Ontology terms and in a curated database of 489 
biological pathways. Of these, 356 pathways (174 KEGG, 114 WikiPathways, 46 Reactome, 
22 Netpath) were significantly enriched in at least one human coexpression group (FDR < 
0.05). Using this approach, 38% of the unannotated robust peaks (35,082 out of 91,269) 
were within a cluster with a significant association to a pathway. The annotated 
coexpression groups are summarized in the website (http://fantom.gsc.riken.jp/5/sstar/
Browse_coexpression_clusters) and a detailed example identifying genes putatively 
involved in influenza A pathogenesis is shown in Extended Data Fig. 10a.
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Introducing sample ontology enrichment analysis (SOEA), we show that expression profiles 
can also be associated with cell, anatomical and disease ontology terms by testing for 
overrepresentation of terms in ranked lists of systematically annotated samples expressing 
each peak (Extended Data Fig. 11 and Supplementary Methods). Novel peaks can be 
annotated in this way. For example, an un-annotated DPI peak at 
hg19::chr18:3659943.3659972, + is linked to the terms classical monocyte (CL:0000860; P 
value = 6.35 × 10−124, Extended Data Fig. 11h) and bone marrow (UBERON:0002371; P 
value = 2.7 × 10−80). Manual examination of the profile confirms the transcript is 
predominantly expressed in myeloid cells with higher levels in CD14+ monocytes. Applied 
to all CAGE peaks, 127,645 human and 44,449 mouse robust peaks were annotated as 
enriched in at least one CL, DOID or UBERON term (Extended Data Fig. 11i, j). The most 
commonly-enriched terms at a P value threshold of 10−20 were classical monocyte (CL:
0000860; 26,634 peaks, 14%), bone marrow (UBERON:0002371; 22,387 peaks, 12%) and 
neural tube (UBERON:0001049; 20,484 peaks, 11%) (Supplementary Table 13). This is 
consistent with the coexpression clustering in Fig. 4 (green and purple spheres correspond to 
leukocyte and central nervous system enriched expression profiles) and indicates that a large 
fraction of the mammalian genome is dedicated to immune and nervous system specific 
functions.
Conclusion
The FANTOM5 promoter atlas is a natural extension of earlier maps of active transcripts 
and promoters complementing the sequencing of mammalian genomes46, 47. It represents an 
advance in an order of magnitude in the wide range of cell types and the amount of data 
produced per sample, and using single-molecule sequencing avoided polymerase chain 
reaction (PCR), digestion and cloning bias48. We have identified and quantified the activity 
of at least one promoter for more than 95% of annotated protein-coding genes in the human 
reference genome; only the activity of 1,225 promoters remains uncharacterized. Some of 
these may not actually be expressed. Some cannot be unambiguously measured with CAGE 
due to copy number variants or closely related multigene families. The remaining promoters 
are probably expressed in rare cell types or during windows of development or states of 
cellular activation that are not readily accessible and remain to be sampled. A continued 
effort to add profiles from these cells will make it possible to integrate them with the 
FANTOM5 data, and to extract metadata to identify those regulatory elements that are new 
and lineage-specific.
The FANTOM5 data highlights the value in profiling primary cells as opposed to whole 
tissues. It also highlights the weakness of using cancer cell lines. The cancer cell lines 
generally fail to cluster in a sample-to-sample correlation graph with their supposed cell type 
or tissue of origin (Extended Data Fig. 12) and express more transcription factors than 
primary cells (Extended Data Fig. 3g). The mutations and chromosomal rearrangements that 
occur in cancer result in unique transcriptional networks that do not exist in the 
untransformed state and do not necessarily generalize across multiple tumours of the same 
type. In terms of building mammalian transcriptional regulatory network models that reflect 
the normal untransformed state, primary cells are the logical choice. They have normal 
genomes, and express in the order of 430 transcription factors at appreciable levels, ranking 
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of which can be used to reduce the complexity further and identify key known regulators of 
cellular phenotypes. Focusing on these key regulators and motif searching in the 
corresponding cell-type-specific promoters provides the data to build cell-type-specific 
regulatory network models and support a rational approach to identification of drivers 
required to reprogram cells from one lineage to another. Promoter-based expression data 
also has direct practical applications in the interpretation (and re-interpretation) of the 
function of single nucleotide polymorphisms (SNPs) in genome-wide association studies 
(GWAS), which commonly occur in non-coding sequences. In accompanying manuscripts, 
reanalysis of several GWAS data sets uncovered new disease associations in FANTOM5 
promoters and identification of regulatory SNPs within enhancers that were active in 
medically relevant samples (ref. 4 and manuscript in preparation). Accordingly, the data will 
enable the design of genotyping arrays and sequence-capture systems to target regulatory 
variation, and the design of promoter constructs allowing researchers to specify the cell-
type-specificity and absolute expression levels of their constructs (particularly for Cre-
conditional knockouts49 and gene therapy vectors50). In all these respects, the FANTOM5 
data set greatly extends the data generated by ENCODE5 to further our knowledge of 
genome function.
METHODS SUMMARY
All Methods are described in full in the Supplementary Information.
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Extended Data
Extended Data Figure 1. Decomposition-based peak identification (DPI)
a, Schematic representation of each step in the peak identification. This starts from CAGE 
profiles at individual biological states (I), subsequently defines tag clusters (consecutive 
genomic region producing CAGE signals) over the accumulated CAGE profiles across all 
the states (II). Within each of the tag cluster, it infers up to five underlying signals 
(independent components) by using ICA independent component analysis (ICA) (III). It 
smoothens each of the independent components and finds peaks where signal is higher than 
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the median (IV). The peaks along the individual components are finally merged if they are 
overlapping each other (V). b, c, Genomic view of actual examples (B4GALT1 locus) for 
human and mouse. CAGE profiles across the biological states (I) are shown as a greyscale 
plot, in which the x axis represents the genomic coordinates and individual rows represent 
individual biological states. Dark (or black) dots indicate frequent observation of 
transcription initiation (that is, larger number of CAGE read counts) and light dots (white) 
indicate less frequency. The blue histogram on the top indicates the accumulated CAGE 
read counts, and the entire region shown represents a single tag cluster (II). The histograms 
below the greyscale plot indicate the independent components of the CAGE signals inferred 
by ICA (III), and the resulting CAGE peaks are shown at the blue bars closest to the bottom 
(V). The bottom track indicates a gene model in RefSeq. The figures overall indicate that 
only one TSS is defined by RefSeq gene models in this locus, however, transcription starts 
from slightly different regions depending on the context, and the DPI method successfully 
captured the different initiation events. d, Breakdown of singleton and composite 
transcription initiation regions with homogenous or heterogeneous expression patterns 
according to likelihood ratio test (see Supplementary Methods).
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Extended Data Figure 2. Broad and sharp promoters
DPI peaks from the permissive set were aggregated by grouping neighbouring peaks less 
than 100 bp apart. Cumulative distribution of CAGE signal along each region was calculated 
and positions of 10th and 90th percentiles were determined. a, Schematic representation of 
CAGE signal within promoter region and calculation of interquantile width. Signal from 
CAGE transcription start sites (CTSS) is shown. Distance between these two positions 
(interquantile width) was used as a measure of promoter width. b, Distribution of promoter 
interquantile width across all 988 human samples. Individual grey lines show distribution in 
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each sample and the average distribution is shown in yellow. For each sample only 
promoters with > = 5 TPM were selected. Distribution of obtained interquantile width was 
clearly bimodal and allowed us to set the empirical threshold at 10.5 bp that separates the 
best sharp from broad promoters. c, Distribution of expression specificity. The distribution 
of log ratios of expression in individual samples against the median expression across all 
samples is shown separately for sharp and broad promoters. Solid line shows the average 
distribution for all samples and the semi-transparent band denotes the 99% confidence 
interval. The dashed line corresponds to an expected log ratio if all samples contributed 
equally to the total expression. d, Average frequency of AA/AT/TA/TT (WW) dinucleotides 
around dominant TSS of sharp (red) and broad (blue) promoters across all human samples. 
Lines show the average signal and semi-transparent bands indicate the 99% confidence 
interval. Closer view of WW dinucleotide frequency displaying 10 bp periodicity is shown 
in the inset and indicates the likely position of the +1 nucleosome. For comparison, the 
signal aligned to randomly chosen TSS in broad promoters is shown in orange. e, As in a but 
for promoters in CD14+ monocytes. H2A.Z signal (subtracted coverage − plus strand 
coverage − minus strand coverage) around sharp and broad promoters is shown in 
corresponding semi-transparent colours (data from ref. 51). Transition point in subtracted 
coverage from positive to negative values indicates the most likely position of the 
nucleosome (shown as semitransparent blue circle) centre. f, As in b but for promoters in 
frontal lobe. H3K4me3 signal (subtracted coverage = plus strand coverage – minus strand 
coverage) around sharp and broad promoters is shown in corresponding semi-transparent 
colours (data from ref. 52).
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Extended Data Figure 3. Density plots of DPI peaks maximum and median expression
a, Distribution for all human robust peaks. b, Distribution for all mouse robust peaks. 
Fraction on left of vertical dashed line corresponds to peaks with non-ubiquitous (cell-type-
restricted) expression patterns (median < 0.2 TPM). Fraction below the diagonal dashed line 
corresponds to ubiquitous-uniform (housekeeping) expression profiles (less than tenfold 
difference between maximum and median). Fraction in top-middle corresponds to 
ubiquitous-non-uniform expression profiles (maximum > tenfold median). c–e Show 
distibutions based on cell line, primary cell and tissue data, respectively. The mixture of 
cells in tissues may overestimate the fraction of ubiquitously expressed genes. f, Boxplot 
showing the number of peaks and detected > = 10 TPM in primary cells, cell lines or tissues. 
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g, As in a but showing transcription factor p1 peaks only. h, Boxplot showing maximum 
expression of the main promoter for transcription factors or all coding genes. i, Density plots 
of human robust DPI peaks maximum and median expression for the main promoter of 
coding genes. j, As in d but showing the main promoter of transcription factors. Fraction on 
the left of the vertical dashed line corresponds to peaks with non-ubiquitous (cell-type-
restricted) expression patterns (median < 0.2 TPM). Fraction below the diagonal dashed line 
corresponds to ubiquitous-uniform (housekeeping) expression profiles (less than tenfold 
difference between max and median). Fraction above the diagonal and to the right of the 
vertical dashed lines corresponds to ubiquitous-non-uniform expression profiles (maximum 
> tenfold median). k, Distribution for peaks with CpG island only (n = 55,897). l, 
Distribution for peaks with only a TATA motif (n = 3,933). m, Distribution for peaks with 
both CpG islands and TATA box motifs (n = 834). n, Distribution for DPI peaks with 
neither a TATA motif nor CpG island (n = 124,152). Fraction on the left of the vertical 
dashed line corresponds to peaks with non-ubiquitous (cell-type-restricted) expression 
patterns (median < 0.2 TPM). Fraction below the diagonal dashed line corresponds to 
ubiquitous-uniform (housekeeping) expression profiles (less than tenfold difference between 
max and median). Fraction above diagonal and to right of vertical dashed lines corresponds 
to ubiquitous-non-uniform expression profiles (maximum > tenfold median).
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Extended Data Figure 4. Cross-species projected super-clusters
a, The number of mouse and human TSSs (both permissive and robust) per projected super-
cluster. b, Same data as presented in panel a, with the y axis on a log scale. There is a slight 
tendency for more human TSSs per super-cluster than mouse TSSs. c, The number of human 
and mouse TSSs per projected super-cluster, density of data points indicated by log-scaled 
colour gradient shown on the right. Most super-clusters contain < = 4 DPI defined TSSs in 
both species. d, Evaluating the conservation of TSS annotation between species. Projected 
super-clusters are annotated by the most functional contributing TSS from each species (see 
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Methods). Grey shading in the margins summarizes the proportion of super-clusters with 
each category of annotation in both mouse (y axis) and human (x axis). Numbers and 
volumes of circles represent counts of projected super-clusters, for example there are 34,868 
super-clusters in which > = 1 human and > = 1 mouse component TSS are annotated as 
protein coding and 719 super-clusters in which the human TSSs are unannotated and at least 
one of the mouse TSSs are annotated as the 5′ end of a non-coding transcript.
Extended Data Figure 5. De novo derived, cell-state-specific motif signatures
a–c, The de novo motif discovery tools DMF, HOMER, ChIPMunk and ScanAll were 
applied to detect sequence motifs enriched in the vicinity of sample-specific peaks (a), 
yielding 8,699 de novo motifs (b). The coverage of known motif space by the de novo 
motifs was evaluated by comparing them to the SWISSREGULON, HOCOMOCO, 
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TRANSFAC, HOMER, JASPAR, and ENCODE LEXICON motif collections. c, The 
remaining 1,221 de novo motifs that were not similar to known motifs were then clustered 
using MACRO-APE, resulting in 169 unique novel motifs. d, Known motifs from the 
HOMER database were annotated and counted in around cell-type-specific TSSs (−300 to 
+50 bp) associated with CpG islands (CGI) or non-CGI regions. e–g, RNA Pol II ChIP-seq 
signal and motif finding in ‘housekeeping gene’ promoters with different absolute 
expression levels. Human housekeeping gene promoters were defined as (log10(max + 0.1) − 
log10(median + 0.1) < = 1). The resulting clusters were then extended by −300 and +50. 
Overlapping extended clusters were removed by only keeping those with the highest 
expression. e, Extended clusters were then split into 5 equal sized bins with decreasing 
absolute expression. f, RNA Pol II occupancy at binned clusters in ENCODE cell lines 
(highly expressed genes show the highest occupancy, but even bin5 clusters showing very 
low tag counts are still highly occupied). g, Bubble plot representation comparing known 
motif enrichments in bin1 (high expression) and bin5 (low expression) extended CAGE 
clusters. The bubble plots encode two quantitative parameters per motif: difference in motif 
occurrence between bin1 (x axis) and bin5 (y axis) as well as the adjusted P values for 
enrichment (bubble diameter). Colouring indicates significantly differentially distributed 
motifs (5% FDR). The right panel additionally summarizes the fraction of clusters in each 
bin that contain the indicated motifs along with the Benjamini Hochberg adjusted 
hypergeometric P value for differential enrichment.
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Extended Data Figure 6. Features of cell-type-specific promoters
a, The distribution of expression log ratios of all individual samples against the median of 
all samples is shown separately for CGI-associated and non-CGI-associated CAGE clusters. 
The dashed line corresponds to an expected log ratio if all samples contribute equally to the 
total expression. b, Histograms for genomic distance distributions of HepG2 DNase I 
hypersensitivity, H3K4me3, H2A.Z, POL2, P300, GABP, YY1, HNF4A, FOXA1 and 
FOXA2 ChIP-seq tag counts centred across CGI-associated and non-CGI-associated CAGE 
clusters (separated according to expression specificities) across a 2 kilobase (kb) genomic 
region. Expression specificity bins are colour-coded (as indicated in the DNase I panel) with 
blue representing the highest degree of specificity. Numbers of regions in bins are given in 
the GABP panel (CGI no. / nCGI no., colour coding as above). c, Histograms for genomic 
distance distributions of ChIP-seq-derived sequence motifs for GABP, YY1, HNF4A, 
FOXA1 and FOXA2 (corresponding to the samples in the lower panel of c) centred across 
CGI-associated and non-CGI-associated CAGE clusters (separated according to expression 
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specificities) across a 2 kb genomic region. Motifs are shown on top. The percentage of 
promoters overlapping with ChIP-seq peaks (b) or consensus sequences (c) for transcription 
factors binding the highest specificity clusters (HNF4A, FOXA2, TCF7L2) is also given in 
blue. d, Plots showing mean expression specificity (high values indicate more constrained 
expression over cells, see the accompanying manuscript4) in enhancers close to RefSeq 
promoters as a function of promoter CpG content and three classes of promoter expression 
specificity.
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Extended Data Figure 7. Extended features of cell-type-specific promoters
a, Distribution of global expression specificity estimated using primary cells, cell lines or 
tissues only. b, Distribution of expression specificity for HepG2, GM12878, HeLaS3, K562 
and CD14+ monocytes (distribution of expression log ratios of all individual samples against 
the median of all samples is shown separately for CGI-associated and nonCGI-associated 
CAGE clusters. The dashed line corresponds to an expected log ratio if all samples 
contribute equally to the total expression). c, Histograms for genomic distance distributions 
of K562 DNase I hypersensitivity, H3K4me3, H2A.Z, POL2, P300, GATA1 ChIP-seq tag 
counts centred across CGI-associated and non-CGI-associated CAGE clusters (separated 
according to expression specificities) across a 2 kb genomic region. Expression specificity 
bins are colour-coded with blue representing the highest degree of specificity. d, DNase I 
hypersensitivity, H3K4me3, H2A.Z, POL2, P300 and IRF4 in GM12878. e, DNase I 
hypersensitivity, H3K4me3, H2A.Z in HeLaS3. f, DNase I hypersensitivity, H3K4me3, 
H2A.Z, PU.1 and CEBPB in CD14+ monocytes.
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Extended Data Figure 8. Transcription factor promoter expression profile clustering
a, Biolayout visualization of transcription factor coexpression in human primary cells (3,775 
nodes, 54,892 edges r > 0.70, MCL2.2). b, Hierarchical coexpression clustering and 
heatmap of ETS family transcription factors across the entire human collection (only 
promoter1(p1) data shown).
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Extended Data Figure 9. Collapsed coexpression network for mouse coexpression groups
One node is one group of promoters. Derived from expression profiles of 116, 277 
promoters across 402 primary cell types, tissues and cell lines (r > 0.75, MCLi = 2.2). For 
display, each group of promoters is collapsed into a sphere, the radius of which is 
proportional to the cube root of the number of promoters in that group. Edges indicate r > 
0.6 between the average expression profiles of each cluster. Colours indicate loosely-
associated collections of coexpression groups (MCLi = 1.2). Labels show representative 
descriptions of the dominant cell type in coexpression groups in each region of the network, 
and a selection of highly-enriched pathways (FDR < 10−4) from KEGG (K), WikiPathways 
(W), Netpath (N) and Reactome (R).
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Extended Data Figure 10. Annotated expression profiles of alternative promoters
Overlay of coexpression groups enriched for genes involved in the KEGG pathway for 
influenza A pathogenesis (hsa:05164; FDR < 0.1, n > 2). a, Collapsed coexpression network 
showing 5 groups enriched for influenza pathogenesis genes: C0 (blue), C26 (purple), C61 
(yellow), C187 (green) and C413 (red). b, Excerpt from KEGG pathway diagram showing 
positions of genes in each coexpression group (background colours as in a). Pathway entities 
that map to two coexpression groups have the background colour of the smaller group, and 
the text/border colour of the larger group. Details and promoter-level displays (edges 
indicate r > 0.75) for two coexpression groups are displayed with transcripts mapping to 
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KEGG pathway highlighted (inset). In this example the KEGG pathway for influenza A 
pathogenesis (hsa:05164) was strikingly over-represented in one small coexpression group 
in particular (C413, P value < 10−11, FDR = 4.5 × 10−10). Of 19 promoters in coexpression 
group 413, eight were present in the KEGG pathway, including RIG-I (DDX58), the gene 
encoding the receptor for the mitochondrial antiviral signalling pathway53. Four of the 
remaining genes (TRIM21, TRIM22, RTP4 and XAF1) were found to be key host 
determinants of influenza virus replication in a high-throughput short interfering RNA 
(siRNA) screen54, whereas another, PLSCR1, is required for a normal interferon response to 
influenza A55. The top five transcription factor expression profiles most correlated with 
C413 were IRF7, IRF9, STAT1, SP100 and ZNFX1, and from motif enrichment analysis, the 
most frequent motifs found in promoters of cluster C413 were potential IRF-binding motifs. 
c, p1@IRF9 and p2@IRF9 expression ranked by the ubiquitously expressed p1@IRF9 
promoter. d, As in a but ranked by expression of p2@IRF9. e, f, Similar to a and b but 
showing expression of p1@TRMT5 (housekeeping profile) and p2@TRMT5 (expressed in 
pathogen challenged monocytes). g, Histogram showing the number of different 
coexpression clusters (see Fig. 4) in which named genes with alternative promoters 
participate. The majority of genes with alternative promoters participate in more than one 
cluster; 17 genes participate in more than 10 different clusters and are not shown on this 
graph.
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Extended Data Figure 11. Sample ontology enrichment analysis (SOEA)
Expression profile-sample ontology associations were tested by Mann–Whitney rank sum 
test to identify cell, disease or anatomical ontology terms over-represented in ranked lists of 
samples expressing each peak. a, p1@CXCL6 enriched in vascular associated smooth 
muscle cells. b, p5@ST8SIA3 enriched in brain tissues. c, Novel peak enriched in mast 
cells. d, p1@KIAA0125 enriched in myeloid leukaemia. e, p1@BRI3 enriched in myeloid 
leukaemia. f, p1@BDNF enriched in fibroblasts. g, Novel peak enriched in leukocytes. h, 
Novel peak enriched in classical monocytes. i, j, Venn diagrams showing degree of overlap 
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between peaks associated to known genes (blue), cell ontology enriched (yellow), Uberon 
anatomical ontology enriched (green) and disease ontology (red). i, At a threshold of 10−20 
(Mann–Whitney rank sum test), 64% (59, 835 out of 93, 558) of the expression profiles of 
human known transcripts and 74% (67, 810 out of 91, 269) of the expression profiles for 
novel transcripts show enrichment for one or more sample ontologies. j, Mouse sample 
ontology enrichment 10−20 threshold. 30% (18, 273 out of 61, 134) known are enriched and 
47% (26, 176 out of 55, 143) novel are enriched.
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Extended Data Figure 12. Sample-to-sample correlation graph
821 nodes are shown, 21,821 edges shown (r>0.75). a, Samples are coloured by sample type 
(primary cell, cell line or tissue). Note the separation of cell lines and primary cells. b, As in 
a, except major subgroups are coloured and labelled separately.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Promoter discovery and definition in FANTOM5
a, Samples profiled in FANTOM5. b, Reproducible cell-type-specific CAGE patterns 
observed for the 266 base CpG island associated B4GALT1 locus transcription initiation 
region hg19:chr9:33167138.33167403. CAGE profiles for CD4+ T cells (blue), CD14+ 
monocytes (gold), aortic smooth muscle cells (green) and the adrenal cortex 
adenocarcinoma cell line SW-13 (red) are shown. A combined pooled profile showing TSS 
distribution across the entire human collection is shown in black. Values on the y axis 
correspond to maximum normalized TPM for a single base in each track. c, Decomposition-
based peak identification (DPI) finds 6 differentially used peaks within this composite 
transcription initiation region (note: peaks are labelled from p1@B4GALT1 with most tag 
support through to p7@B4GALT1 with the least tag support; p4@B4GALT1 is not shown 
and is in the 3′ UTR of the locus at position hg19::chr9:33111241.33111254−). Note in 
particular one large broad region on the left used in all samples and a sharp peak to the right, 
preferentially used in the aortic smooth muscle cells. d, Venn diagram showing DPI defined 
peaks expressed at ≥10 TPM in primary cells (red), tissues (blue) and cell lines (green). e, 
Fraction of unannotated peaks observed in subsets of d. P, primary cells, T, tissues, C, cell 
lines, PT, TC, PC and PTC correspond to peaks found in multiple sample types, for 
example, PT, found in primary cells and tissue samples.
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Figure 2. Cell-type-restricted and housekeeping transcripts encoded in the mammalian genome
a, Density plot summarizing the distribution of relative log expression (RLE) normalized 
maximum and median TPM expression values for the 185K robustly detected human peaks 
identified by FANTOM5 (colour bar on right indicates relative density). Box and whiskers 
plots above and to right show distribution of median and maximum values in the data set 
(box shows the interquartile range). Promoters of named genes are highlighted to show 
extremes of expression level and expression breadth, note the alternative promoters of IRF9 
and TRMT5 have different maximums and breadths of expression (see Extended Data Fig. 
10). Fraction on left of the red vertical dashed line corresponds to peaks detected in less than 
50% of samples with non-ubiquitous (cell-type-restricted) expression patterns (median < 0.2 
TPM). Fraction below the red diagonal dashed line corresponds to ubiquitous-uniform 
(housekeeping) expression profiles (maximum < 10× median). Fraction above diagonal and 
to the right of the vertical dashed lines corresponds to ubiquitous-non-uniform expression 
profiles (maximum > 10× median). b, Box and whisker plots showing the distribution of 
expression levels for the same peaks as in a across the 889 samples (box shows the 
interquartile range).
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Figure 3. TSS conservation as a function of expression properties and functional annotation
a, b, Human robust TSS coordinates were projected through EPO12 whole genome multiple 
sequence alignments (Supplementary Methods). The y-axis values show the fraction of 
human TSSs that align to an orthologous position in the indicated species. The x axis shows 
the relative divergence of macaque, dog and mouse genomes as the substitution rate at 
fourfold degenerate sites in protein coding sequence. The TSS locations were genome 
permuted (Supplementary Methods) and then projected through EPO12 alignments to give 
the null expectation (dashed blue line). The 95% confidence intervals of 1, 000 samples of 1, 
000 TSS are shown (blue shading). a, TSS mapped to the 5′ ends of protein coding and non-
coding transcripts are labelled (C and N, respectively), those that do not map to a known 
transcript 5′ end are shown as the ‘anonymous’ category. With the exception of anonymous, 
all robust TSSs represented in both panels are associated with the 59 ends of previously 
annotated transcripts. Non-ubiquitous (cell-type-restricted), ubiquitous-uniform 
(housekeeping) and non-uniform-ubiquitous were defined as in Fig. 2. Ultra-housekeeping 
TSSs were defined as those with less than fivefold difference between maximum and 
median. The category top 1000 UDE represents the 1,000 ubiquitous TSSs that are most 
differentially expressed4. There are 1,016 ultra-housekeeping TSSs, 276 ubiquitous-uniform 
non-coding TSSs and all other categories contain over 2, 000 TSSs. b, Same axes as panel a 
showing TSSs with expression that is biased towards a single expression facet (larger 
mutually exclusive grouping of the primary cell and tissue samples based on the sample 
ontologies CO and UBERON, defined in ref. 4). Only expression facets with greater than 
250 enriched TSSs are shown. For clarity, only a subset of expression facets are coloured 
and labelled.
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Figure 4. Coexpression clustering of human promoters in FANTOM5
Collapsed coexpression network derived from 4,882 coexpression groups (one node is one 
group of promoters; 4,664 groups are shown here) derived from expression profiles of 
124,090 promoters across all primary cell types, tissues and cell lines (visualized using 
Biolayout Express3D (ref. 45), r > 0.75, MCLi = 2.2). For display, each group of promoters 
is collapsed into a sphere, the radius of which is proportional to the cube root of the number 
of promoters in that group. Edges indicate r > 0.6 between the average expression profiles of 
each cluster. Colours indicate loosely-associated collections of coexpression groups (MCLi 
= 1.2). Labels show representative descriptions of the dominant cell type in coexpression 
groups in each region of the network, and a selection of highly-enriched pathways (FDR < 
10−4) from KEGG (K), WikiPathways (W), Netpath (N) and Reactome (R). Promoters and 
genes in the coexpression groups are available online at (http://fantom.gsc.riken.jp/5/data/).
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